Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
April 30 2020 - 6:50AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl,
M.D., as its new executive vice president and chief medical
officer. Dr. Lebwohl brings decades of biopharmaceutial leadership
and drug development experience, and joins Intellia to lead its
clinical development and regulatory organizations.
“Dr. Lebwohl joins Intellia during an exciting time
for the company, as we continue to rapidly progess our first
systemic CRISPR/Cas9-based therapy to the clinic. David’s vast
experience in rare diseases, engineered cell therapy and clinical
development complement our R&D capabilities and leadership team
strength,” said Intellia President and Chief Executive Officer John
Leonard, M.D. “He has been at the helm of premier development
organizations that launched breakthrough oncology therapies to
patients, most notably the recent CAR-T therapy, Kymriah®, and the
multi-indication blockbuster, Afinitor®. Under his leadership, we
look forward to the impact he can make in delivering Intellia’s
CRISPR/Cas9-based treatments to patients.”
Dr. Lebwohl’s Professional and Academic
Credentials
Dr. Lebwohl’s career spans three decades in the
biopharmaceutical industry, successfully bringing novel medicines
through all phases of clinical trials and global regulatory
approvals. During his career, he has overseen multiple full-scale
development programs with more than 200 clinical studies across
myriad indications. He joins Intellia from Semma Therapeutics,
Inc., where he was chief medical officer and led the company’s
regenerative medicine efforts using stem-cell-derived pancreatic
islets to cure type I diabetes starting in November 2018. Semma was
acquired by Vertex Pharmaceuticals Inc., in October 2019. Prior to
his role at Semma, Dr. Lebwohl held numerous senior-level drug
development leadership positions at the global healthcare company,
Novartis Pharmaceuticals Inc. (Novartis), where most recently he
was senior vice president and franchise global program head, CAR-T,
Promacta and SEG101 Global Program Teams, responsible for the
development of the breakthrough therapy Kymriah®
(tisagenlecleucel), approved for the treatment of B-cell acute
lymphoblastic leukemia. Dr. Lebwohl also was responsible for
numerous other Novartis oncology drug development programs, and led
the company’s Cell and Gene Therapies Unit. Under his leadership,
the blockbuster drug, Afinitor® (everolimus), was approved for five
indications including metastatic breast, kidney, brain and lung
cancers. Prior to working at Novartis, Dr. Lebwohl spent five years
at Bristol Myers Squibb, Inc., where he worked in the Oncology
Clinical Development group at the company’s Pharmaceutical Research
Institute. He is a well-recognized medical oncologist, with
certifications in hematology and internal medicine.
Dr. Lebwohl received an undergraduate degree in
Biochemical Sciences from Harvard College, and an M.D. from the
Yale University School of Medicine. He completed his fellowship
training at Memorial Sloan Kettering Cancer Center, and his
residency in Internal Medicine at Brigham and Women’s Hospital in
Boston. He has authored more than 50 peer-reviewed
publications.
“I am thrilled to join Intellia’s leadership team
as we propel the first systemic CRISPR/Cas9 genome editing
treatment to the clinic this year,” said Dr. Lebwohl. “I am
passionate about working on the next generation of treatments, like
genome editing therapies, that are both game-changing for medical
practice and can address the unmet needs of patients. I look
forward to leading the Development organization and building on the
company’s clinical capabilities.”
About Intellia
Therapeutics
Intellia Therapeutics is a leading genome
editing company focused on developing proprietary, curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course, and through improved cell therapies that
can treat cancer and immunological diseases, or can replace
patients’ diseased cells. The combination of deep scientific,
technical and clinical development experience, along with its
leading intellectual property portfolio, puts Intellia in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and
CRISPR/Cas9 at intelliatx.com and follow us on Twitter
@intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking
statements” of Intellia Therapeutics, Inc. (“Intellia” or
the “Company”) within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, express or implied statements
regarding Intellia’s ability to advance and expand the CRISPR/Cas9
technology to develop into human therapeutic products; our ability
to achieve stable or effective genome editing; our ability to
administer our CRISPR/Cas9 product candidates; the potential timing
and advancement of our preclinical studies and clinical studies,
including for our ATTR program, AML program and other programs; the
timing and potential achievement of milestones to advance our
pipeline, including nominating development candidates and filing
INDs; the modularity of our platform and our ability to replicate
or apply results achieved in our preclinical studies, including
those in our ATTR and AML programs, in any future studies,
including human clinical trials; our ability complete successful
IND-enabling toxicology studies of NTLA-2001, our lead ATTR
development candidate, and subsequently submitting an IND
application in 2020 that will be accepted by the regulatory
agencies; our growth as a company and the anticipated contribution
of the members of our board of directors and our executives to our
operations and progress; the impact of our collaborations on our
development programs; the potential timing of regulatory filings
regarding our development programs; and our ability to fund
operations through the end of 2021.
Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
of future events, and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: risks related to Intellia’s ability to
protect and maintain its intellectual property position; risks
related to Intellia’s relationship with third parties, including
its licensors and licensees; risks related to the ability of its
licensors to protect and maintain their intellectual property
position; uncertainties related to the initiation and conduct of
studies and other development requirements for its product
candidates; the risk that any one or more of Intellia’s product
candidates will not be successfully developed and commercialized;
the risk that the results of preclinical studies or clinical
studies will not be predictive of future results in connection with
future studies; and the risk that Intellia’s collaborations with
Novartis, Regeneron or its other ex vivo collaborations
will not continue or will not be successful. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Intellia’s actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in Intellia’s most recent
annual report on Form 10-K as well as discussions of potential
risks, uncertainties, and other important factors in Intellia’s
other filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Intellia undertakes no duty to update this information unless
required by law.
Media:
Jennifer Mound SmoterSenior Vice PresidentExternal
Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Lynnea OlivarezDirectorExternal Affairs &
Communications+1 956-330-1917lynnea.olivarez@intelliatx.com
Investors:
Lina Li Associate Director Investor Relations +1
857-706-1612lina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024